Search clinical trials for: Attention Deficit Disorder with Hyperactivity -- *therapy

Total 256761 results

Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
University of California, Los Angeles
National Institute of Mental Health (NIMH)

Completed

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder (Project1)

Attention Deficit Disorder With Hyperactivity

United States
Purdue Pharma, Canada

Completed

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

Attention Deficit Hyperactivity Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

Attention Deficit Hyperactivity Disorder

United States
Chang Gung Memorial Hospital

Enrolling by invitation

Endocrine Disrupting Chemicals and Hormones in ADHD (ADHD)

Attention Deficit Hyperactivity Disorder

Taiwan
Ironshore Pharmaceuticals and Development, Inc

Completed

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD (HLD100-103)

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
Duke University
National Institute of Mental Health (NIMH)

Completed

Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD

Attention Deficit Hyperactivity Disorder

United States
Shire

Completed

Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.

Attention Deficit Disorder With Hyperactivity
Massachusetts General Hospital
ElMindA Ltd

Terminated

Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study

Bipolar Disorder | Autism Spectrum Disorder | Attention Deficit Hyperactivity Disorder

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Shire

Withdrawn

A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators

Attention Deficit Hyperactivity Disorder

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations

Attention Deficit Hyperactivity Disorder

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Shire

Completed

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, United States, Germany, Poland, Italy, Ukraine, Romania, United Kingdom, Sweden, Austria, Canada, France, Ireland
Shire

Completed

Efficacy and Safety of SPD465 in Adults With ADHD

Attention Deficit Disorder With Hyperactivity
Ironshore Pharmaceuticals and Development, Inc

Completed

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD (CEES)

Attention Deficit Hyperactivity Disorder

United States
Shire

Completed

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

Attention-Deficit/Hyperactivity Disorder

United States
Gregory Fabiano

Completed

Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD

Attention Deficit Disorder With Hyperactivity

United States
University Hospital, Tours

Completed

Identification of Biomarkers of Attention Deficit Disorder With or Without Hyperactivity (ADHD) by a Metabolomic Approach in Children (METHADA)

Adhd

France
Shire

Completed

Safety and Efficacy of SPD465 in Adults With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Shire

Completed

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder

United States
Shire

Completed

Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe

Attention Deficit Hyperactivity Disorder (ADHD)

Spain, Germany, Ukraine, France, Italy, Austria, Belgium, Ireland, Netherlands, Poland, Romania, Sweden, United Kingdom
Shire

Completed

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

ADHD

United States
Shire

Completed

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Attention-Deficit Hyperactivity Disorder

United States
Shire

Completed

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention-deficit/Hyperactivity Disorder

Spain, Belgium, United States, Netherlands, United Kingdom, Italy, Germany, Canada, France, Sweden
Shire

Completed

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Attention-Deficit/Hyperactivity Disorder

United States, Poland, Spain, Canada, Hungary, Belgium, Germany, Italy, Sweden, United Kingdom
Shire

Completed

Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

Attention Deficit Disorder With Hyperactivity
Shire

Completed

Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

Germany, Italy, Poland, Spain, Romania, Belgium, Hungary, Netherlands, Sweden, United Kingdom
Shire

Completed

Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

Attention Deficit Disorder With Hyperactivity
Shire

Completed

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Attention-deficit/Hyperactivity Disorder

United States, Canada, Germany, Hungary, Sweden
Shire

Completed

Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

Attention Deficit Disorder With Hyperactivity
Shire

Completed

Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
Shire

Completed

Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

ADHD

United States
Shire

Completed

Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD Specifically With Executive Function Impairment

United States
Shire

Completed

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Attention-Deficit/Hyperactivity Disorder

United States, Canada
Shire

Completed

Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Attention-deficit/Hyperactivity Disorder

United States
Shire

Completed

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)

ADHD

United States
Shire

Completed

Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Terminated

Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder
Shire

Completed

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Withdrawn

Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD

United States
Shire

Completed

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD

Attention Deficit Disorder With Hyperactivity

United States

3

Subscribe